RT Journal Article
SR Electronic
T1 Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20066407
DO 10.1101/2020.04.15.20066407
A1 National COVID Testing Scientific Advisory Panel
A1 Emily R Adams
A1 Mark Ainsworth
A1 Rekha Anand
A1 Monique I Andersson
A1 Kathryn Auckland
A1 J Kenneth Baillie
A1 Eleanor Barnes
A1 Sally Beer
A1 John Bell
A1 Tamsin Berry
A1 Sagida Bibi
A1 Miles Carroll
A1 Senthil Chinnakannan
A1 Elizabeth Clutterbuck
A1 Richard J Cornall
A1 Derrick W Crook
A1 Thushan De Silva
A1 Wanwisa Dejnirattisai
A1 Kate E Dingle
A1 Christina Dold
A1 Alexis Espinosa
A1 David W Eyre
A1 Helen Farmer
A1 Maria Fernandez Mendoza
A1 Dominique Georgiou
A1 Sarah J Hoosdally
A1 Alistair Hunter
A1 Katie Jeffrey
A1 Paul Klenerman
A1 Julian Knight
A1 Clarice Knowles
A1 Andrew J Kwok
A1 Ullrich Leuschner
A1 Robert Levin
A1 Chang Liu
A1 Cesar Lopez-Camacho
A1 Jose Carlos Martinez Garrido
A1 Philippa C Matthews
A1 Hannah McGivern
A1 Alexander J Mentzer
A1 Jonathan Milton
A1 Juthathip Mongkolsapaya
A1 Shona C Moore
A1 Marta S Oliveira
A1 Fiona Pereira
A1 Elena Perez Lopez
A1 Timothy Peto
A1 Rutger J Ploeg
A1 Andrew Pollard
A1 Tessa Prince
A1 David J Roberts
A1 Justine K Rudkin
A1 Veronica Sanchez
A1 Gavin R Screaton
A1 Malcolm G Semple
A1 Donal T Skelly
A1 Jose Slon-Campos
A1 Elliot Nathan Smith
A1 Alberto Jose Sobrino Diaz
A1 Julie Staves
A1 David Stuart
A1 Piyada Supasa
A1 Tomas Surik
A1 Hannah Thraves
A1 Pat Tsang
A1 Lance Turtle
A1 A Sarah Walker
A1 Beibei Wang
A1 Charlotte Washington
A1 Nicholas Watkins
A1 James Whitehouse
YR 2020
UL http://medrxiv.org/content/early/2020/07/07/2020.04.15.20066407.abstract
AB Background The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance of ELISA and lateral flow immunoassay (LFIA) devices.Methods We tested plasma for COVID (SARS-CoV-2) IgM and IgG antibodies by ELISA and using nine different LFIA devices. We used a panel of plasma samples from individuals who have had confirmed COVID infection based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142).Results ELISA detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection (sensitivity 85%, 95%CI 70-94%), vs. 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 COVID-positive individuals tested ≥10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar.Conclusions Currently available commercial LFIA devices do not perform sufficiently well for individual patient applications. However, ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.Competing Interest StatementNoneFunding StatementThis study was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, the UK Government Department of Health and Social Care and and grants from NIHR [award CO-CIN-01] and the Medical Research Council [grant MC_PC_19059]. DC, TEAP and ASW are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (NIHR200915). Blood donor and QUOD samples were provided with support from NHS Blood and Transplant and the Medical Research Council UK. SKC is supported by Medical Research Council UK. TdS is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). DWE is a Robertson Foundation Fellow and NIHR Oxford BRC Senior Research Fellow. PM is a Wellcome Trust Clinical Research Fellow (110110/Z/15/Z) and NIHR Oxford BRC Senior Research Fellow. AM, PK, SCM, TPr, MGS and LT are supported by NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (HPRU-EZI) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with the University of Oxford and Liverpool School of Tropical Medicine (award number NIHR200907). EB, PK, AJP and ASW are NIHR Senior Investigators. PK (WT109965/MA) and GRS (095541/A/11/Z) are Wellcome Trust Senior Investigators. JR is supported by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (Grant 101237/Z/13/B). The views expressed are the author(s) and are not necessarily those of the NHS, the NIHR, the UK Department of Health and Social Care, the MRC or PHE.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResults generated for all samples and relevant metadata is provided in Table S7. https://doi.org/10.12688/wellcomeopenres.15927.1